Several brokerages have updated their recommendations and price targets on shares of AbbVie (NYSE: ABBV) in the last few weeks:
- 7/26/2024 – AbbVie had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $200.00 price target on the stock.
- 7/26/2024 – AbbVie had its price target raised by analysts at Wells Fargo & Company from $200.00 to $205.00. They now have an “overweight” rating on the stock.
- 7/26/2024 – AbbVie had its price target raised by analysts at Barclays PLC from $187.00 to $200.00. They now have an “overweight” rating on the stock.
- 7/26/2024 – AbbVie had its “buy” rating reaffirmed by analysts at Truist Financial Co.. They now have a $210.00 price target on the stock, up previously from $195.00.
- 7/19/2024 – AbbVie had its price target raised by analysts at BMO Capital Markets from $180.00 to $214.00. They now have an “outperform” rating on the stock.
- 7/11/2024 – AbbVie had its price target raised by analysts at Morgan Stanley from $191.00 to $196.00. They now have an “overweight” rating on the stock.
- 7/9/2024 – AbbVie had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $200.00 price target on the stock.
- 7/3/2024 – AbbVie had its “overweight” rating reaffirmed by analysts at Piper Sandler Companies. They now have a $190.00 price target on the stock.
- 7/2/2024 – AbbVie had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $190.00 price target on the stock.
- 6/20/2024 – AbbVie had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $200.00 price target on the stock.
- 6/18/2024 – AbbVie had its price target raised by analysts at Piper Sandler from $185.00 to $190.00. They now have an “overweight” rating on the stock.
- 6/5/2024 – AbbVie was upgraded by analysts at HSBC Holdings plc from a “hold” rating to a “buy” rating. They now have a $185.00 price target on the stock.
AbbVie Price Performance
Shares of NYSE:ABBV traded down $0.51 on Wednesday, hitting $186.27. The company’s stock had a trading volume of 1,503,329 shares, compared to its average volume of 5,547,360. The company has a 50-day simple moving average of $168.50 and a 200 day simple moving average of $169.93. AbbVie Inc. has a 1 year low of $135.85 and a 1 year high of $187.71. The company has a market capitalization of $328.93 billion, a PE ratio of 55.27, a PEG ratio of 2.39 and a beta of 0.64. The company has a debt-to-equity ratio of 7.93, a current ratio of 0.94 and a quick ratio of 0.83.
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Thursday, July 25th. The company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.08. The company had revenue of $14.46 billion for the quarter, compared to analysts’ expectations of $14.02 billion. AbbVie had a return on equity of 186.82% and a net margin of 9.71%. AbbVie’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period last year, the firm posted $2.91 EPS. Sell-side analysts forecast that AbbVie Inc. will post 10.86 EPS for the current fiscal year.
AbbVie Announces Dividend
Insider Activity at AbbVie
In related news, Chairman Richard A. Gonzalez sold 282,845 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $175.00, for a total transaction of $49,497,875.00. Following the transaction, the chairman now directly owns 513,099 shares of the company’s stock, valued at approximately $89,792,325. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.25% of the stock is currently owned by insiders.
Hedge Funds Weigh In On AbbVie
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Capital Advisors Ltd. LLC grew its position in AbbVie by 1.3% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 4,453 shares of the company’s stock worth $764,000 after acquiring an additional 55 shares during the last quarter. Lokken Investment Group LLC grew its position in shares of AbbVie by 3.6% in the 4th quarter. Lokken Investment Group LLC now owns 1,666 shares of the company’s stock worth $258,000 after buying an additional 58 shares during the last quarter. Arcadia Investment Management Corp MI grew its position in shares of AbbVie by 0.6% in the 1st quarter. Arcadia Investment Management Corp MI now owns 9,371 shares of the company’s stock worth $1,706,000 after buying an additional 59 shares during the last quarter. RAM Investment Partners LLC grew its position in shares of AbbVie by 1.1% in the 2nd quarter. RAM Investment Partners LLC now owns 5,219 shares of the company’s stock worth $895,000 after buying an additional 59 shares during the last quarter. Finally, L. Roy Papp & Associates LLP grew its position in shares of AbbVie by 0.8% in the 2nd quarter. L. Roy Papp & Associates LLP now owns 7,892 shares of the company’s stock worth $1,354,000 after buying an additional 60 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Further Reading
- Five stocks we like better than AbbVie
- What is a SEC Filing?
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- Options Trading – Understanding Strike Price
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- What is the Hang Seng index?
- 5 Aggressive Growth Stocks for Long-Term Investors
Receive News & Ratings for AbbVie Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc and related companies with MarketBeat.com's FREE daily email newsletter.